Bio-Path Holdings reports financial results for Q3 2024, including net loss of $2.1 million.

From GlobeNewswire: 2024-11-15 07:00:00

Bio-Path Holdings, Inc. announced its financial results for Q3 2024, revealing a net loss of $2.1 million. The company expanded its DNAbilize® technology into an obesity program and saw swift enrollment in a clinical trial for AML patients. They also closed a $4.0 million private placement.

In October, Bio-Path initiated a therapeutic program for obesity using BP1001-A to target insulin resistance. They completed enrollment for the third dosing cohort in the Phase 1/1b clinical trial of BP1002 for venetoclax-resistant AML patients. An article highlighting the anti-tumor effect of BP1003 in various cancers was published in Biomedicines.

A patient in the Phase 1/1b advanced solid tumor clinical trial responded positively to BP1001-A, demonstrating a 15% reduction in the primary tumor. The trial is moving to higher dose levels and may include combinations with paclitaxel and gemcitabine. Bio-Path reported a net loss of $2.1 million for Q3 2024.

Bio-Path Holdings will host a conference call today to discuss the financial results and recent developments. The company’s DNAbilize® technology is being used to develop RNAi nanoparticle drugs for cancer treatments. The lead product candidate, prexigebersen (BP1001), is in Phase 2 for blood cancers, and BP1001-A is in a Phase 1/1b study for solid tumors.



Read more at GlobeNewswire:: Bio-Path Holdings Reports Third Quarter 2024 Financial